15 results about "Coated capsule" patented technology

The present invention relates to an enteric-coated capsule for the release of a sedative and / or analgesic and / or relaxing active ingredient, comprising a capsule base body having a capsule wall that is closed on all sides and forming a cavity within which the active ingredient is arranged.

The utility model discloses a continuous packaging device for a capsule box structure, which comprises an equipment rack provided with a plane turntable, and at least four capsule box placing positions are arranged on the plane turntable; the equipment rack is sequentially provided with a feeding work station, a film covering work station, a hot press molding work station and a discharging work station on the outer side of the plane rotary table; the switching of different working positions is realized through the rotation of the rotary table; the feeding work station is used for containing capsule boxes. The film laminating work station is provided with a film laminating mechanism for carrying out plastic packaging film matching on the capsule box; a hot-pressing head is arranged at the hot-pressing molding work station and is used for carrying out hot-pressing molding on the capsule box coated with the film so as to ensure sealing; the discharging work station is provided with a discharging assembly which comprises a guiding channel, an ejecting mechanism and a push rod and is used for ejecting the capsule box out of the containing station and pushing the capsule box into the guiding channel to complete discharging. According to the utility model, the structure is simple, the production efficiency can be improved, the packaging cost can be reduced, and the high efficiency, stability and reliability of the packaging process can be ensured.

The invention discloses an efficient preparation and purification method of active pharmaceutical ingredients in rhaponticum uniflorum. The method comprises the steps of pretreatment of raw materials in the flowering stage, vacuum low-temperature countercurrent extraction, membrane coupling purification, resin-crystal combined refining and active ingredient activation. In the pretreatment, ventilating and drying at 40-50 DEG C until the water content is less than or equal to 8%, crushing and sieving with a 40-60-mesh sieve Carrying out dynamic countercurrent extraction in a three-stage series device by using gradient ethanol under the conditions that the temperature is 45 + / -2 DEG C and the pressure is-0.08 to-0.1 MPa; the preparation method comprises the following steps: carrying out microfiltration with a 0.22 [mu] m ceramic membrane and concentration with a 1000Da ultrafiltration membrane, carrying out gradient elution with an HPD-100 resin column, adding a linarin-spinosin (3: 1) seed crystal, crystallizing at 4 DEG C, and finally freeze-drying and activating. According to the present invention, the obtained active component total flavone content is more than or equal to 85%, the iridoid retention rate is more than or equal to 95%, the Nrf2 pathway activation EC50 is less than or equal to 0.12 mg / mL, the APAP liver injury mouse serum ALT is reduced by 55-70% due to the dosage of 80 mg / kg, the active component can be prepared into the enteric capsule for treating the drug-induced liver injury, and the problems of component degradation, low purity and short resin life in the prior art are effectively solved.

The application discloses a duloxetine hydrochloride enteric-soluble capsule, which is composed of a capsule shell and content, wherein the content is a micro-pellet containing duloxetine hydrochloride, and the micro-pellet is composed of a blank pellet core, a drug-loading layer, an isolation layer, an enteric-soluble layer and a protective layer. The binder of the isolation layer of the enteric-soluble capsule micro-pellet contains both high-viscosity hypromellose and low-viscosity hypromellose. Through improvement of the composition of the isolation layer, the dissolution curve of the duloxetine hydrochloride enteric-soluble capsule meets the standard requirements, the 90-minute dissolution degree is obviously improved, and the stability is superior to that of a reference preparation.

The application belongs to the technical field of medicine, and particularly relates to a self-releasing microcapsule for intestinal sampling and application thereof. The self-releasing microcapsule comprises a capsule cavity, a capsule shell, a sealing member and a coating. The capsule shell is provided with a sampling hole, the capsule cavity is internally provided with sampling hydrogel for absorbing sample fluid, the sealing member is arranged in the capsule cavity between the sampling hydrogel and the sampling hole, wherein the expansion of the sampling hydrogel in the capsule cavity presses the sealing member to engage with the sampling hole to seal the capsule cavity, and the coating is arranged on the surface of the capsule shell. The coating comprises the following coating materials in parts by weight: 15-20 parts of hydroxypropyl methyl cellulose phthalate, 25-30 parts of Eudragit L100, 8-12 parts of algal extract, 1-3 parts of polyethylene glycol and 1-2 parts of talc. The self-releasing microcapsule can be used for precise sampling of the colon.

The invention relates to an oral polypeptide preparation and a preparation method thereof, in particular to an oral polypeptide preparation, an oral polypeptide enteric capsule and a preparation method of the oral polypeptide enteric capsule, and the oral polypeptide preparation comprises polypeptide medicine, ionic liquid or deep eutectic solvent, silicon dioxide and enteric material. The oral polypeptide enteric capsule comprises a polypeptide drug, an ionic liquid or a deep-eutectic solvent, an adsorption material and a hollow enteric capsule, wherein the surfaces of drug-carrying particles formed by the polypeptide drug, the ionic liquid or the deep-eutectic solvent and the adsorption material are not provided with coating layers, and the drug-carrying particles are directly filled into the hollow enteric capsule. The preparation disclosed by the invention can realize stability of the polypeptide drug and promote absorption of the polypeptide drug, and the polypeptide drug is almost not released in the stomach and is more quickly released in the intestinal tract.

The invention provides an omeprazole enteric capsule and a preparation method thereof, and belongs to the technical field of medicines. The omeprazole enteric-coated capsule is prepared by taking an omeprazole derivative as an active component and embedding the omeprazole derivative through a sustained-release enteric-coated material. According to the omeprazole enteric capsule prepared by the invention, by adjusting the molecular structure of omeprazole, the water solubility and the bioavailability of omeprazole are improved, the half-life period is prolonged, and by embedding the sustained-release enteric material, the targeted slow release of intestinal tracts is realized, so that the drug effect time is prolonged, the problem of repeated medication is avoided, the compliance of patients is improved, and the bioavailability of the omeprazole enteric capsule is improved. Wide application prospects are realized.

The invention belongs to the technical field of medicines, and particularly relates to a self-release microcapsule for intestinal sampling and application thereof. The self-release microcapsule comprises a capsule cavity, a capsule shell, a sealing element and a coating; a sampling hole is formed in the capsule shell, and sampling hydrogel is filled in a capsule cavity and is used for absorbing sample fluid; the sealing element is arranged in the bag cavity between the sampling hydrogel and the sampling hole, and expansion of the sampling hydrogel in the bag cavity presses the sealing element to be connected with the sampling hole so as to seal the bag cavity; the coating is arranged on the surface of the capsule shell; the coating is prepared from the following coating materials in parts by weight: 15 to 20 parts of hydroxypropyl methylcellulose phthalate, 25 to 30 parts of EudragL100, 8 to 12 parts of algae extract, 1 to 3 parts of polyethylene glycol and 1 to 2 parts of talcum powder. The self-release microcapsule provided by the invention can be used for accurate sampling of colon.

The invention discloses a nicotinamide ribose capsule and a preparation method thereof, and belongs to the technical field of medicines. The nicotinamide ribose capsule comprises a capsule shell material and an in-capsule composition, the capsule shell is made of a hydroxypropyl methylcellulose enteric capsule shell; the intracapsular composition is prepared from the following components in parts by mass: 80 to 90 parts of nicotinamide ribose coated particles, 0.5 to 2 parts of edible silicon dioxide, 3 to 6 parts of catechin, 1 to 3 parts of microcrystalline cellulose, 1.5 to 3.5 parts of calcium hydrogen phosphate and 1 to 2 parts of magnesium stearate; the nicotinamide ribose coated particles are L-cysteine salt of nicotinamide ribose with a coating layer on the surface, and the coating layer is prepared by spray-drying a coating solution through a fluidized bed; the coating solution is prepared from shellac, algin, triethyl citrate, glyceryl monostearate and a solvent. The nicotinamide ribose capsule provided by the invention has a three-layer protection mechanism, a physical barrier and chemical protection are combined, and the stability of the nicotinamide ribose capsule is improved.

This invention relates to an anti-brittle enteric-coated gelatin hollow capsule shell, belonging to the field of hollow capsule production technology. Addressing the problems of low mechanical strength, easy breakage during storage and transportation, and increased brittleness due to high coating ratios in existing enteric-coated capsule shells, this invention significantly improves the anti-brittleness of the capsule shell while ensuring enteric properties. It utilizes a synergistic compounding of gelatin, humectants, surfactants, plasticizers, modifiers, disintegrants, opacifiers, and enteric coating materials, combined with a "step-by-step coating and online precise temperature-controlled drying" process. The product meets the pharmacopoeia's brittleness requirements for a 20g weight and passes a 100g weight strengthening test. It exhibits structural stability, low breakage rate, and is suitable for high-load packaging transportation and long-term storage, making it widely applicable to various enteric-coated drug formulations.

The utility model discloses a ketoprofen enteric capsule filling machine internal circulation feeding device which comprises a fixing frame, a material box is fixedly arranged at the upper end of the fixing frame, a discharging inclined pipe is fixedly arranged on one side of the material box in a communicating mode, and a second feeding port is fixedly formed in the upper end of the material box in a communicating mode. And an elevator is fixedly arranged on one side of the second feeding opening. By means of the structure, the feeding port is formed in one side of the elevator, the fixing plate is arranged on one side of the upper end of the elevator, the motor is arranged at the upper end of the fixing plate, the conveying belt is arranged on one side of the motor, and the multiple hoppers are arranged at the upper end of the conveying belt, so that ketoprofen enteric-coated particles in the hoppers drive the conveying belt to ascend through the motor, and the feeding efficiency is improved; a first push plate is arranged at the upper end of the first electric push rod, a second electric push rod is arranged on one side in the material box, and a second push plate is arranged on one side of the second electric push rod, so that blockage caused by more ketoprofen enteric-coated particles fed at a time is avoided.

The invention provides a budesonide enteric capsule, which is characterized in that resveratrol is used as a pellet core, budesonide, zein, hydroxypropyl methylcellulose acetate succinate, polyvinylpyrrolidone, acetyl triethyl citrate and tween-80 are used for preparing a budesonide sustained-release pellet, and the budesonide enteric capsule is prepared from the budesonide, the zein, the hydroxypropyl methylcellulose acetate succinate, the polyvinylpyrrolidone, the acetyl triethyl citrate and the tween-80. Cellulose acetate phthalate and zinc pectin are adopted to prepare the budesonide enteric-coated sustained-release pellet, and the budesonide enteric-coated capsule prepared through filling has the enteric-coated characteristic, and the effect is better than that of single use of cellulose acetate phthalate or zinc pectin as an enteric-coated material; and the budesonide enteric capsule prepared by taking resveratrol as the pellet core has better ulcerative colitis treatment effect than the budesonide enteric capsule prepared by taking cane sugar as the pellet core.

The present invention relates to a modified-release solid oral pharmaceutical composition, which is in the form of an enteric-coated capsule, wherein said capsule comprises cannabidiol (CBD), tetrahydrocannabinol (THC) and an emulsifier, and wherein the capsule optionally further comprises one or more cannabis terpenes. The solid oral pharmaceutical composition provided herein has a particularly advantageous modified release profile as well as an improved oral bioavailability as compared to conventional formulations of CBD and THC.

The invention relates to the technical field of pharmaceutical preparations, and discloses an aceclofenac enteric capsule and application thereof in rheumatoid arthritis, and the aceclofenac enteric capsule composition comprises the following components in parts by weight: aceclofenac, choline-aspartate ionic liquid, sodium alginate, low methoxyl pectin and micronized calcium carbonate. The invention aims to solve the technical problems that aceclofenac is poor in solubility and a conventional enteric-coated preparation has a burst release effect. According to the composition, a pH-sensitive in-situ gel drug delivery system is constructed; when the content of the composition is in a gastric acid environment, micronized calcium carbonate is activated and calcium ions are released in situ; and after entering the neutral environment of the intestinal tract, the calcium ions are crosslinked with the sodium alginate and the low-methoxyl pectin, so that the liquid content is quickly converted into semi-solid gel with biological adhesiveness. The system realizes the positioning retention and long-acting slow release of the medicine in the intestinal tract, effectively avoids the violent fluctuation of the blood concentration, and is expected to improve the bioavailability of the medicine.

The application discloses a kind of micro-pellet type omeprazole enteric-coated capsules and preparation method thereof, including drug-containing pills, isolation layer and enteric layer, wherein the drug-containing pills comprise omeprazole, carboxymethyl chitosan, low-substituted hydroxypropyl cellulose, binder, filler and stabilizer;The mass ratio of omeprazole, carboxymethyl chitosan and low-substituted hydroxypropyl cellulose is 1:0.2-0.4:0.05-0.25;The micro-pellet type omeprazole enteric-coated capsule of the application does not contain organic solvent and surfactant, and the auxiliary material is simple, the micro-pellet particle size is uniform, the roundness is good, the surface finish is good, not easy to break, and the drug release effect is stable.